-
公开(公告)号：US20170107293A1
公开(公告)日：2017-04-20
申请号：US15311016
申请日：2015-05-15
发明人： Björn Frendéus , Ingrid Teige , Linda Mårtensson , Mark Cragg , Ali Roghanian
CPC分类号： C07K16/2887 , A61K9/0034 , A61K9/0048 , A61K9/0095 , A61K9/02 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/4858 , A61K9/4866 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/38 , A61K2039/507 , A61K2039/55 , C07K16/283 , C07K16/2893 , C07K16/30 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
摘要： Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.
-
公开(公告)号：US20140314793A1
公开(公告)日：2014-10-23
申请号：US14250898
申请日：2014-04-11
IPC分类号： C07K16/30
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2821 , C07K16/2833 , C07K16/4283 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/94
摘要： The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.
摘要翻译： 本发明提供了结合分子，包括选择性结合靶细胞的细胞表面抗原的抗体分子，并且其中结合分子在细胞表面抗原结合时诱导靶细胞的细胞死亡。 还提供了用于细胞死亡诱导的方法和药物组合物及其用途。
-
公开(公告)号：US11447549B2
公开(公告)日：2022-09-20
申请号：US16633740
申请日：2018-07-26
发明人： Björn Frendéus , Linda Mårtensson , Monika Semmrich , Ingrid Teige , Stephen Beers , Aymen Al-Shamkhani , Juliet Gray , Martin Glennie
IPC分类号： A61K39/395 , C07K16/28 , A61K39/00
摘要： Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
-
公开(公告)号：US09803013B2
公开(公告)日：2017-10-31
申请号：US14250898
申请日：2014-04-11
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2821 , C07K16/2833 , C07K16/4283 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/94
摘要： The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.
-
-
-
搜索结果
4 条记录 (耗时 0.03 秒)
